Literature DB >> 23365133

Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.

Zongjian Zhu1, Weiqin Jiang, John N McGinley, Henry J Thompson.   

Abstract

Dietary energy restriction (DER) inhibits experimentally induced mammary cancer, an effect accompanied by elevated levels of silent information regulator 2 (SIRT1), a class III histone deacetylase (HDAC). However, the effect of DER on targets of other classes of HDACs has not been reported, a highly relevant issue given evidence that HDAC induction favors the development of cancer and tumor growth. Experiments were carried out to determine whether suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor with broad activity, would affect the anti-cancer activity of DER. Female Sprague Dawley rats (n = 30/group) were injected with 1-methyl-1-nitrosourea (50 mg/kg) at 21 days of age and 7 days thereafter were randomized to groups fed: (i) control diet (AIN-93G), (ii) 0.1% SAHA (w/w), (iii) 40% DER, or (iv) 0.1% SAHA + 40% DER. An additional group was fed 0.1% SAHA + 40%DER for 5 weeks and released to control diet for 3 weeks. DER significantly reduced mammary cancer incidence, multiplicity, and cancer burden and prolonged cancer latency (P < 0.01). Cancer inhibition was maintained in SAHA + DER, despite evidence that histone (H2A(Lys9), H2B(Lys5), and H4(Lys5/8/12/16), but not H3(Lys9); P < 0.001) and non-histone protein deacetylation (p53(Lys373) and p53(Lys382); P < 0.001) induced by DER was reversed by SAHA. This indicates that the inhibition of DER of cancer is not dependent on HDAC induction. After releasing rats from DER + SAHA, cancer multiplicity remained lower than control (P < 0.05), consistent with apoptosis-mediated cell deletion. These findings support further investigation of the hypothesis that HDAC induction by DER blunts its anti-carcinogenic impact.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365133      PMCID: PMC4636215          DOI: 10.1158/1940-6207.CAPR-12-0449-T

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  39 in total

1.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Authors:  D Li; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

Review 2.  Are sirtuins viable targets for improving healthspan and lifespan?

Authors:  Joseph A Baur; Zoltan Ungvari; Robin K Minor; David G Le Couteur; Rafael de Cabo
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

3.  A comparison of the histopathology of premalignant and malignant mammary gland lesions induced in sexually immature rats with those occurring in the human.

Authors:  M Singh; J N McGinley; H J Thompson
Journal:  Lab Invest       Date:  2000-02       Impact factor: 5.662

Review 4.  Sirtuin 1 (SIRT1): the misunderstood HDAC.

Authors:  Walter Stünkel; Robert M Campbell
Journal:  J Biomol Screen       Date:  2011-11-15

5.  Classification of premalignant and malignant lesions developing in the rat mammary gland after injection of sexually immature rats with 1-methyl-1-nitrosourea.

Authors:  H J Thompson; M Singh; J McGinley
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-04       Impact factor: 2.673

Review 6.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

Authors:  P A Marks; V M Richon; R A Rifkind
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

Review 7.  Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks.

Authors:  Sebastian Alers; Antje S Löffler; Sebastian Wesselborg; Björn Stork
Journal:  Mol Cell Biol       Date:  2011-10-24       Impact factor: 4.272

8.  Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).

Authors:  L A Cohen; S Amin; P A Marks; R A Rifkind; D Desai; V M Richon
Journal:  Anticancer Res       Date:  1999 Nov-Dec       Impact factor: 2.480

9.  Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

Authors:  Leonard A Cohen; Paul A Marks; Richard A Rifkind; Shantu Amin; Dhimant Desai; Brian Pittman; Victoria M Richon
Journal:  Anticancer Res       Date:  2002 May-Jun       Impact factor: 2.480

10.  Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats.

Authors:  Weiqin Jiang; Zongjian Zhu; Henry J Thompson
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

View more
  4 in total

1.  Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.

Authors:  Andrés E Quesada; Binara Assylbekova; Christine E Jabcuga; Rongzhen Zhang; Michael Covinsky; Adan Rios; Nghia D Nguyen; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.

Authors:  Andrés E Quesada; Nghia D Nguyen; Adan Rios; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

3.  A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.

Authors:  Vivek Subbiah; Robert E Brown; Mary F McGuire; Jamie Buryanek; Filip Janku; Anas Younes; David Hong
Journal:  Oncotarget       Date:  2014-01-15

4.  Cell Signaling Pathways in Mammary Carcinoma Induced in Rats with Low versus High Inherent Aerobic Capacity.

Authors:  Tymofiy Lutsiv; John N McGinley; Elizabeth S Neil; Henry J Thompson
Journal:  Int J Mol Sci       Date:  2019-03-26       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.